Literature DB >> 24867394

Idiopathic pulmonary fibrosis: evolving concepts.

Jay H Ryu1, Teng Moua2, Craig E Daniels2, Thomas E Hartman3, Eunhee S Yi4, James P Utz2, Andrew H Limper2.   

Abstract

Idiopathic pulmonary fibrosis (IPF) occurs predominantly in middle-aged and older adults and accounts for 20% to 30% of interstitial lung diseases. It is usually progressive, resulting in respiratory failure and death. Diagnostic criteria for IPF have evolved over the years, and IPF is currently defined as a disease characterized by the histopathologic pattern of usual interstitial pneumonia occurring in the absence of an identifiable cause of lung injury. Understanding of the pathogenesis of IPF has shifted away from chronic inflammation and toward dysregulated fibroproliferative repair in response to alveolar epithelial injury. Idiopathic pulmonary fibrosis is likely a heterogeneous disorder caused by various interactions between genetic components and environmental exposures. High-resolution computed tomography can be diagnostic in the presence of typical findings such as bilateral reticular opacities associated with traction bronchiectasis/bronchiolectasis in a predominantly basal and subpleural distribution, along with subpleural honeycombing. In other circumstances, a surgical lung biopsy may be needed. The clinical course of IPF can be unpredictable and may be punctuated by acute deteriorations (acute exacerbation). Although progress continues in unraveling the mechanisms of IPF, effective therapy has remained elusive. Thus, clinicians and patients need to reach informed decisions regarding management options including lung transplant. The findings in this review were based on a literature search of PubMed using the search terms idiopathic pulmonary fibrosis and usual interstitial pneumonia, limited to human studies in the English language published from January 1, 2000, through December 31, 2013, and supplemented by key references published before the year 2000.
Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24867394     DOI: 10.1016/j.mayocp.2014.03.016

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  36 in total

Review 1.  Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?

Authors:  Christopher L Mosher; Robert J Mentz
Journal:  Am Heart J       Date:  2020-05-06       Impact factor: 4.749

2.  AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis.

Authors:  Malik Bisserier; Javier Milara; Yassine Abdeldjebbar; Sarah Gubara; Carly Jones; Carlos Bueno-Beti; Elena Chepurko; Erik Kohlbrenner; Michael G Katz; Sima Tarzami; Julio Cortijo; Jane Leopold; Roger J Hajjar; Yassine Sassi; Lahouaria Hadri
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

3.  Idiopathic Pulmonary Fibrosis and Myasthenia Gravis: An Unusual Association.

Authors:  Bharti Chogtu; Daliparty Vasudev Malik; Rahul Magazine
Journal:  J Clin Diagn Res       Date:  2016-04-01

Review 4.  Translating the Science of Aging into Therapeutic Interventions.

Authors:  James L Kirkland
Journal:  Cold Spring Harb Perspect Med       Date:  2016-03-01       Impact factor: 6.915

5.  miR-26a suppresses EMT by disrupting the Lin28B/let-7d axis: potential cross-talks among miRNAs in IPF.

Authors:  Haihai Liang; Shanshan Liu; Yang Chen; Xue Bai; Li Liu; Yuechao Dong; Meiyu Hu; Xiaomin Su; Yingzhun Chen; Longtao Huangfu; Xuelian Li; Yunyan Gu; Hongli Shan
Journal:  J Mol Med (Berl)       Date:  2016-01-20       Impact factor: 4.599

6.  Proliferation of adult human bronchial epithelial cells without a telomere maintenance mechanism for over 200 population doublings.

Authors:  Jennifer R Peters-Hall; Jaewon Min; Enzo Tedone; Sei Sho; Silvia Siteni; Ilgen Mender; Jerry W Shay
Journal:  FASEB J       Date:  2019-11-22       Impact factor: 5.191

7.  Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects.

Authors:  Elena Bargagli; Viola Bonti; Katia Ferrari; Elisabetta Rosi; Alessandra Bindi; Maurizio Bartolucci; Moroni Chiara; Luca Voltolini
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

8.  Evaluation of choroidal thickness, retinal vascular caliber, and nerve fiber layer thickness in idiopathic interstitial pneumonia.

Authors:  Erhan Ugurlu; Gokhan Pekel; Betul Cengiz; Kerem Bozkurt; Goksel Altinisik
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

9.  Clinical strategies and animal models for developing senolytic agents.

Authors:  James L Kirkland; Tamara Tchkonia
Journal:  Exp Gerontol       Date:  2014-10-28       Impact factor: 4.032

10.  Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care.

Authors:  Sergio Harari; Michele Davì; Alice Biffi; Antonella Caminati; Alessandra Ghirardini; Valeria Lovato; Claudio Cricelli; Francesco Lapi
Journal:  Intern Emerg Med       Date:  2019-09-20       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.